Cargando…

Use of Casirivimab and Imdevimab for the Treatment of COVID-19

The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cock...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ryan, Mangal, Rohan, Stead, Thor S, Barbera, Andrew R, Ganti, Latha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449254/
https://www.ncbi.nlm.nih.gov/pubmed/36106219
http://dx.doi.org/10.7759/cureus.27766
_version_ 1784784254281973760
author Liu, Ryan
Mangal, Rohan
Stead, Thor S
Barbera, Andrew R
Ganti, Latha
author_facet Liu, Ryan
Mangal, Rohan
Stead, Thor S
Barbera, Andrew R
Ganti, Latha
author_sort Liu, Ryan
collection PubMed
description The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2.
format Online
Article
Text
id pubmed-9449254
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-94492542022-09-13 Use of Casirivimab and Imdevimab for the Treatment of COVID-19 Liu, Ryan Mangal, Rohan Stead, Thor S Barbera, Andrew R Ganti, Latha Cureus Emergency Medicine The authors present three cases of unvaccinated coronavirus disease 2019 (COVID-19) patients who exhibited symptoms of fever, sore throat, nausea, diarrhea, congestion, and headache. Although they refused COVID-19 vaccination, they presented for the casirivimab and imdevimab monoclonal antibody cocktail, which resulted in the resolution of all symptoms. The authors describe the mechanisms and importance of monoclonal antibody treatment for high-risk and unvaccinated patients infected with SARS-CoV-2. Cureus 2022-08-08 /pmc/articles/PMC9449254/ /pubmed/36106219 http://dx.doi.org/10.7759/cureus.27766 Text en Copyright © 2022, Liu et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Emergency Medicine
Liu, Ryan
Mangal, Rohan
Stead, Thor S
Barbera, Andrew R
Ganti, Latha
Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title_full Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title_fullStr Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title_full_unstemmed Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title_short Use of Casirivimab and Imdevimab for the Treatment of COVID-19
title_sort use of casirivimab and imdevimab for the treatment of covid-19
topic Emergency Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449254/
https://www.ncbi.nlm.nih.gov/pubmed/36106219
http://dx.doi.org/10.7759/cureus.27766
work_keys_str_mv AT liuryan useofcasirivimabandimdevimabforthetreatmentofcovid19
AT mangalrohan useofcasirivimabandimdevimabforthetreatmentofcovid19
AT steadthors useofcasirivimabandimdevimabforthetreatmentofcovid19
AT barberaandrewr useofcasirivimabandimdevimabforthetreatmentofcovid19
AT gantilatha useofcasirivimabandimdevimabforthetreatmentofcovid19